Advertisement

Search Results

Advertisement



Your search for ,OUr matches 10724 pages

Showing 4701 - 4750


hematologic malignancies
lymphoma

Treatment Update on Selected Non-Hodgkin Lymphomas

As part of The ASCO Post’s coverage of the 2019 ASCO Annual Meeting, featured here are four abstracts from different clinical trials evaluating newer treatments for Waldenström’s macroglobulinemia and T-cell lymphomas. Waldenström’s Macroglobulinemia ABSTRACT 7509: Outcomes with bendamustine plus ...

skin cancer

Is Vitamin A Intake Linked to Cutaneous Squamous Cell Carcinoma Risk?

People whose diets included high levels of vitamin A had a 17% reduction in risk for developing cutaneous squamous cell carcinoma, as compared to those who ate modest amounts of foods and supplements rich in vitamin A. These findings were published by Kim et al in JAMA Dermatology. Vitamin A is...

survivorship

Preserving Sexuality and Restoring Sexual Function in Male and Female Cancer Survivors

Intimacy changes after a cancer diagnosis. Both male and female survivors can experience significant sexual dysfunction, pain with sex, loss of desire, and a slew of other clinical and psychological sequelae. To make matter worse, sexual function is often not discussed by patients and their...

lymphoma

FDA Requests Manufacturer Recall of Some Textured Breast Implants

On July 24, the U.S. Food and Drug Administration (FDA) requested that Allergan, the manufacturer of a specific type of textured breast implant, recall specific models of its textured implants from the U.S. market due to the risk of breast implant–associated anaplastic large cell lymphoma (ALCL)....

lung cancer

Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer

In patients with extensive-stage small cell lung cancer (SCLC), adding trilaciclib to standard-of-care chemotherapy demonstrated meaningful delays in deterioration of myelosuppression-related symptoms, according to Jared Weiss, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill,...

breast cancer
kidney cancer
sarcoma
lymphoma
multiple myeloma

Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers

The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...

symptom management
immunotherapy

What Causes Liver Injury During Treatment With Pembrolizumab?

Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a...

issues in oncology

Gender Equity

Diversity, inclusion, and gender equality were prevalent themes for 2019 that ran throughout the ASCO Annual Meeting. From the first year that featured free onsite child care for attendees, to a session on “Establishing a Mutually Respectful Environment in the Workplace,” as well as a Plenary...

supportive care
palliative care
pain management

How an Innovative AI-Based Smartphone Application Is Addressing Patients’ Palliative Care Needs

GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development.   During the 2019...

mektovi
erbitux
braftovi

BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer

The three-drug combination of encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to the results of the phase III BEACON CRC clinical trial....

solid tumors
immunotherapy

Cell-Free DNA Sequencing Highly Concordant With Tissue-Based Testing in the Detection of Microsatellite Instability Status

Microsatellite instability (MSI) is an important predictive biomarker of response to immune checkpoint blockade in solid cancers. However, despite recommendations by clinical practice guidelines, MSI is often not assessed, usually due to tissue insufficiency, unavailability, or infeasibility....

gynecologic cancers

Prognostic Biomarker for Progression of Moderate Cervical Dysplasia

In a study published by Louvanto et al in Clinical Infectious Diseases, researchers investigated the ability of a DNA methylation panel to determine between disease progression and regression among women of childbearing age with untreated cervical intraepithelial dysplasia. In the majority of...

gynecologic cancers

Hysterectomy-Corrected Uterine Corpus Cancer Incidence in the United States

In a study reported in the Journal of Clinical Oncology, Clarke et al found that hysterectomy-corrected rates of uterine corpus cancer—particularly nonendometrioid subtypes—have been increasing in the United States, with racial disparities in incidence and survival being observed. In...

immunotherapy

What Causes Liver Injury During Treatment With Pembrolizumab?

Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...

lymphoma

Can Treatment With Antibiotics Inhibit Malignant T Cells in Cutaneous T-Cell Lymphoma?

Many patients with cutaneous T-cell lymphoma contract Staphylococcus aureus infections in the skin. In a new study, researchers have shown that aggressive treatment with antibiotics for patients with these infections not only inhibits the staphylococcal bacteria—but also the cancer...

issues in oncology
global cancer care

WHO Releases Report on the Global Tobacco Epidemic

Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures—four times more people than a decade ago. However, a new World Health...

lymphoma

Germline BRCA2 Mutations and Risk of Pediatric or Adolescent Lymphoma

A research letter published by Wang et al in JAMA Oncology has found that inherited mutations in the BRCA2 gene are linked to an increased risk for non-Hodgkin lymphoma in children and adolescents. “The BRCA family of genes are known to be linked to risk for breast and...

bladder cancer

Conditional Reprogramming of Urine Cultures for Bladder Cancer

A research team led by investigators from Georgetown University Medical Center and Fudan University in China has devised a noninvasive and individualized technique for detecting and treating bladder cancer. Their findings were published by Jiang et al in Protein & Cell. The method uses a...

lung cancer
issues in oncology

Deep Natural Language Processing of Oncology Radiology Reports

Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...

Director of the FDA’s Oncology Center of Excellence Discusses Expanded Access, Accelerated Drug Approvals in Latest ASCO in Action Podcast

THE DIRECTOR OF the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), Richard Pazdur, MD, joins ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, in the latest ASCO in Action Podcast to discuss the FDA’s new program to make it easier for physicians to...

issues in oncology

Is It Time to Reevaluate the P Value in Biomedical Research?

Developed in 1925 by British statistician Sir Ronald Fisher, the P value is a measure that is ever-present in abstracts and studies, a small statistical tool that has enormous power to aid research being published in the literature or support drug approval. Over the past several years, however, a...

Jason S. Lewis, PhD, Receives SNMMI Award for Outstanding Achievement in Basic Nuclear Medicine Science

Jason S. Lewis, PhD, has been named the 2019 recipient of the Paul C. Aebersold Award. Dr. Lewis is the Emily Tow Jackson Chair in Oncology and Vice Chair for Research and Chief Attending, Radiochemistry and Imaging Sciences Service, Department of Radiology at Memorial Sloan Kettering Cancer...

multiple myeloma

FDA Grants Accelerated Approval to Selinexor in Combination With Dexamethasone in Pentarefractory Multiple Myeloma

On July 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two ...

prostate cancer

Study Highlights on Novel Agents and Supportive Care Strategies in Prostate Cancer

In addition to our regular coverage of major news stories from the 2019 ASCO Annual Meeting, here is an additional roundup of important studies related to prostate cancer. ARAMIS: Darolutamide and Quality of Life Darolutamide, a next-generation androgen receptor antagonist, significantly prolonged...

global cancer care

How the ASCO Breakthrough Global Summit Is Bringing Together Innovators to Transform Cancer Care

Earlier this year, ASCO announced plans for its first-ever international meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, which will be held October 11–13, 2019, in Bangkok, Thailand. The meeting is a joint effort by ASCO and the Thai Society of Clinical Oncology to bring...

issues in oncology

No Man Is an Island: Reflections From an ASCO IDEA Recipient

IT WAS a chilly Chicago morning, and I was sitting at the lobby of my hotel when I saw a smiling gentleman cheerfully waving at me from his car. It was Lawrence H. Einhorn, MD, picking me up for our drive to Indiana. I was one of the recipients of the ASCO International Development and Education...

Two Takeaways From Study on Active Surveillance for Prostate Cancer

A population-based study of men with low-risk to intermediate-risk prostate cancer found that 18 months after choosing active surveillance, only 15% were fully compliant with recommendations for active surveillance from the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines ...

prostate cancer

Active Surveillance for Early-Stage Prostate Cancer Requires Active Participation by Patient and Clinician

Active surveillance of patients with early-stage prostate cancer “is tackling the problem of overtreatment” and, with rigorous monitoring, “is safe and allows us to treat only patients who need treatment when their cancer progresses,” Ronald C. Chen, MD, MPH, affirmed in an interview with The ASCO...

lymphoma
issues in oncology

FDA Requests Manufacturer Recall of Some Textured Breast Implants

Today, the U.S. Food and Drug Administration (FDA) requested that Allergan, the manufacturer of a specific type of textured breast implant, recall specific models of its textured implants from the U.S. market due to the risk of breast implant–associated anaplastic large cell lymphoma (ALCL)....

hepatobiliary cancer

Radiofrequency Ablation vs Minimally Invasive Surgery for Small Hepatocellular Carcinoma

In a retrospective analysis published by Si et al in Surgical Endoscopy, researchers found minimally invasive surgery led to higher survival and lower local recurrence in patients with small hepatocellular carcinoma vs radiofrequency ablation, whereas radiofrequency ablation was associated with...

issues in oncology

Physicians and the Threat of Nuclear War

The Hippocratic Oath calls on physicians to “use treatment to help the sick according to my ability and judgment,” but not all versions of the oath call on us to prevent disease. Here we urge our colleagues to acknowledge that additional mandate and renew their commitment to preventing what could ...

issues in oncology
health-care policy

The Unhealthy Health-Care System, and How to Fix It

BOOKMARK Title: An American Sickness: How Healthcare Became Big Business and How You Can Take It BackAuthor: Elisabeth Rosenthal, MDPublisher: Penguin PressPublication Date: April 2017Price: $27.95, hardcover; 416 pages The United States spends considerably more on health care than all other...

Emergency Medicine Doctor Reflects on 5 Decades of Career Experiences

BOOKMARK Title: Patient Care: Death and Life in the Emergency RoomAuthor: Paul Seward, MDPublisher: CatapultPublication Date: July 2018Price: $22.95, hardcover, 240 page The history of emergency medicine residency training is interlaced with the impetus for specialty status in emergency medicine,...

A Compassionate Family Doctor Sparked an Interest in Medicine for Lori Pierce, MD, FASTRO, FASCO

GUEST EDITOR Jame Abraham, MD, FACP Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series of articles, guest editor Jame Abraham, MD,...

lung cancer

Winship Cancer Institute Awarded Lung Cancer SPORE Grant From NCI

The Winship Cancer Institute of Emory University has been awarded a 5-year, $9.7 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to study new approaches for lung cancer treatment. It is reportedly the only grant of its kind to be awarded in...

breast cancer

Timing of Postoperative Treatment After Diagnosis of Breast Cancer and Survival

When chemotherapy is recommended as part of a treatment plan, women with breast cancer should start postoperative treatment ideally within 4 months of their cancer diagnosis. New study findings published by Kupstas et al in the Annals of Surgical Oncology show delaying chemotherapy further is...

issues in oncology

Indiana Oncology Society Launches Cancer Caucus to Serve Local Policymakers

A bipartisan group of Indiana legislators, oncology experts, and other stakeholders joined together on March 6 in Indianapolis for the first-ever Indiana Cancer Caucus, where they discussed approaches to improve access to quality health care, invest in cancer research funding, and address critical ...

issues in oncology

Study Looks at Effect of Parenthood, Gender on Conference Attendance and Early Career Satisfaction

For oncologists in the beginning of their careers, scientific conferences present an opportunity to network, share research, gain new knowledge, and advance in their career. However, many women find themselves skipping these conferences because of family obligations, a new research letter published ...

pancreatic cancer

Artificial Intelligence to Guide Management of Pancreatic Cysts

In a proof-of-concept study, an international scientific team has shown that a laboratory test using artificial intelligence tools has the potential to more accurately sort out which people with pancreatic cysts will eventually develop pancreatic cancers. Their findings were published by Springer...

prostate cancer
issues in oncology

Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients

In a report published by Jayadevappa et al in JAMA Network Open, researchers found that among older patients with prostate cancer, treatment with androgen-deprivation therapy (ADT) was associated with a subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10...

lung cancer
issues in oncology

Poorer Outcomes for Patients With Lung Cancer Undergoing Radiotherapy During Disaster-Level Hurricanes

Patients who experienced a disaster-level hurricance during radiotherapy for lung cancer had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival. These findings come from a...

lung cancer
gastroesophageal cancer
bladder cancer
gastrointestinal cancer
immunotherapy

Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma

Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...

hepatobiliary cancer

Role of IL-6/JAK1 Pathway in the Treatment of Hepatocellular Carcinoma

A recent study published by Chan et al in the Journal of Clinical Investigation found a cellular pathway associated with cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma. IL-6/JAK1 Pathway Researchers...

breast cancer

Role of Regulatory T Cells in Predicting Breast Cancer Relapse

Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...

Biden Cancer Initiative Suspends All Operations

Today, the Biden Cancer Initiative announced it would suspend all operations. The Initiative, which launched on June 26, 2017, is an independent nonprofit organization that was built on the goals of the White House Cancer Moonshot program created by President Barack Obama and led by Vice President ...

issues in oncology

Economic Burden of Cancer in the United States in 2015

There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer is the second-leading cause of death...

bladder cancer

Study Identifies Key Biologic Features of Upper Tract Urothelial Carcinoma

A new study published by Robinson et al in Nature Communications aimed to learn more about the biologic characteristics of upper tract urothelial carcinoma to help develop more targeted therapies. “We discovered the defining biologic characteristics of [upper tract urothelial tumors] that...

leukemia

Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia

In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia. The trial,...

hepatobiliary cancer

KIR-HLA System Gene Loci Imbalance and Biliary Tract Cancer

Patients with biliary tract cancer have an altered genetic architecture in some immune system receptor systems, according to research published by Cornillet et al in Gastroenterology. Research Findings Researchers at Karolinska Institutet investigated the genetic architecture of two large genetic ...

multiple myeloma
immunotherapy

How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy

Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...

Advertisement

Advertisement




Advertisement